Hyperhidrosis Treatment Market - By Type, Treatment, Age, End-user, Global Forecast 2024-2032

Description

Hyperhidrosis Treatment Market size is projected to expand at 5.3% CAGR from 2024 to 2032, led by rapid advancements in treatment options along with the expansion of dermatology and aesthetic clinics.

Of late, innovations are helping in developing more effective and targeted therapies, such as new medications and minimally invasive procedures to reach a broader patient base. Moreover, dermatology and aesthetic clinics are also increasing their capacity and services to offer specialized treatments for hyperhidrosis for enhancing patient access and care. For instance, in June 2024, Botanix Pharmaceuticals announced that the U.S. FDA had approved its Sofdra (sofpironium) gel, 12.45%, for treating excessive underarm sweating, marking a significant advancement in hyperhidrosis treatment options.

The overall market is segregated into type, treatment, age, end-user, and region.

Based on treatment, the hyperhidrosis treatment market value from the botulinum toxin injections segment is estimated to rise at significant rate from 2024 to 2032 due to rising adoption for offering individuals more control over their symptoms and enhancing quality of life. This approach involves injecting small amounts of botulinum toxin into areas affected by excessive sweating, such as the underarms, palms, or feet. Moreover, healthcare providers are expanding the use of these injections to offer more personalized and targeted treatments for patients.

Hyperhidrosis treatment industry from the dermatology clinics end-user segment is anticipated to expand at substantial CAGR up to 2032, owing to the growing requirement to offer specialized treatments for hyperhidrosis. These clinics are incorporating advanced therapies, such as botulinum toxin injections and new topical treatments to address excessive sweating effectively. Dermatologists are also working on refining treatment protocols and providing personalized care plans to better manage hyperhidrosis symptoms.

Regionally, the Europe hyperhidrosis treatment market size is projected to expand between 2024 and 2032, on account of the rising disposable incomes and the growing cosmetic and aesthetic sector. The cosmetic and aesthetic sectors in the region are integrating new therapies and technologies to address hyperhidrosis more effectively. Additionally, increasing efforts are enhancing treatment options and expanding availability. The ongoing enhancements for offering better solutions and increasing the overall treatment efficacy for individuals seeking relief from excessive sweating across Europe will favor the industry growth.

Product Code: 9862

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of hyperhidrosis
  - 3.2.1.2 Growing awareness and diagnosis rates
  - 3.2.1.3 Advancements in treatment technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects and risk associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Axillary hyperhidrosis
5.3 Palmar hyperhidrosis
5.4 Plantar hyperhidrosis
5.5 Other types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Topical treatment
6.3 Oral medication
- 6.3.1 Anticholinergics
- 6.3.2 Other oral medications
6.4 Botulinum toxin injections
6.5 Iontophoresis
6.6 Surgical treatment

Chapter 7 Market Estimates and Forecast, By Age, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Below 50 years
7.3 Above 50 years

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Ambulatory surgical centers
8.4 Dermatology clinics
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 AbbVie Inc.
10.2 Avanor Healthcare Ltd.
10.3 Brickell Biotech Inc.
10.4 Dermadry Laboratories Inc.
10.5 Dermavant Sciences Inc.
10.6 Hugel, Inc.
10.7 Eirion Therapeutics, Inc
10.8 Eli Lilly and Company
10.9 Intas Pharmaceuticals Ltd
10.10 Kaken Pharmaceutical Co., Ltd.
10.11 Maruho Co., Ltd.
10.12 miraDry, Inc.
10.13 SweatBlock